IP Library › Granted Patent US 12,358,993
Granted Patent B2
US 12,358,993 · App. 17/531,368 · Granted Jul 15, 2025

Methods for the treatment of thyroid eye disease

Inventors: David Madden (Mount Kisco, NY); Kathleen Gabriel (Voorhees, NJ); Guido Magni (Basel, CH); Richard Woodward (Phoenixville, PA); Shao-Lee Lin (Lake Forest, IL); Jeffrey W. Sherman (Lincolnshire, IL)
Assignee: HORIZON THERAPEUTICS IRELAND DAC
C07K16/2863A61K9/0019A61K9/08A61K9/19A61K39/3955A61K45/06A61K47/183A61K47/26A61P27/02C07K16/241C07K16/248C07K16/2887A61K2039/505A61K2039/54A61K2039/545C07K2317/21C07K2317/565C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,358,993
App. No.
17/531,368
Granted
Jul 15, 2025
Kind
B2
Abstract

The invention provides a method of treating or reducing the severity of thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), or a symptom or aspect thereof, in subjects that have undergone prior treatment for TAO, TED, or GO, and either did not respond to said prior treatment or relapsed after said prior treatment. The invention also provides antibodies, or antigen binding fragments thereof, and pharmaceutical compositions useful in the disclosed methods.

Claims (55)

1. A method of treating thyroid eye disease (TED) in a relapsed subject, the method comprising administering to the relapsed subject an antibody that specifically binds to and inhibits insulin like growth factor-I receptor (IGF IR), and wherein said antibody administered to the relapsed subject is administered by intravenous infusion at a dosage of about 10 mg/kg as a first dose following relapse, and at a dosage of about 20 mg/kg in subsequent doses following relapse,

wherein the subject has relapsed after a prior treatment regimen with said antibody,

and wherein said antibody comprises a heavy chain comprising CDRH1, CDRH2, and CDRH3 and a light chain comprising CDRL1, CDRL2, and CDRL3, as set forth in SEQ ID NOs: 1-6, respectively.

2. The method of claim 1 , wherein the antibody comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 7 and a light chain variable region comprising the sequence of SEQ ID NO: 8.

3. The method of claim 2 , wherein the antibody is a human monoclonal antibody.

4. The method of claim 3 , wherein the antibody is teprotumumab.

5. The method of claim 1 , wherein the prior treatment regimen comprises intravenous infusion of said antibody in a first dose of about 10 mg/kg and in subsequent doses of about 20 mg/kg.

6. The method of claim 1 , wherein the subsequent doses are administered every three weeks for at least 21 weeks.

7. The method of claim 6 , wherein the antibody is teprotumumab.

8. The method of claim 1 , wherein the relapsed subject has an increase in proptosis of 2 mm or greater in an eye after completion of the prior treatment regimen.

9. The method of claim 1 , wherein the relapsed subject has an absolute clinical activity score (CAS) of 4 or greater in an eye after completion of the prior treatment regimen.

10. The method of claim 1 , wherein the relapsed subject has a new onset of double vision after completion of the prior treatment regimen.

11. The method of claim 1 , wherein the antibody is teprotumumab.

12. The method of claim 1 , wherein the relapsed subject has relapsed within 48 weeks after completion of the prior treatment regimen.

13. The method of claim 12 , wherein said antibody is teprotumumab, and wherein the prior treatment regimen comprises administration of teprotumumab by intravenous infusion at a first dose of about 10 mg/kg and in subsequent doses of about 20 mg/kg every three weeks, for a total of eight infusions.

14. The method of claim 13 , wherein the relapsed subject has relapsed after responding to the prior treatment regimen with teprotumumab, wherein the responding to the prior treatment regimen comprises a reduction of 2 mm or more in proptosis in an eye.

15. The method of claim 1 , wherein said antibody is teprotumumab, and wherein administration of teprotumumab to the relapsed subject reduces proptosis by at least 2 mm in an eye and/or reduces the CAS in the subject by at least 2 points.

16. The method of claim 15 , wherein administration of teprotumumab to the relapsed subject reduces proptosis by at least 2 mm in an eye.

17. The method of claim 15 , wherein administration of teprotumumab to the relapsed subject reduces the CAS in the subject by at least 2 points.

18. The method of claim 1 , wherein the relapsed subject has relapsed after responding to the prior treatment regimen, wherein the responding to the prior treatment regimen comprises a reduction of 2 mm or more in proptosis in an eye, and wherein administration of said antibody to the relapsed subject reduces proptosis by at least 2 mm in an eye.

19. A method of treating thyroid eye disease (TED) in a relapsed subject in need thereof comprising:

a) identifying a subject who has relapsed after responding to a prior treatment regimen with an antibody that specifically binds to and inhibits IGF IR, and wherein the subject is relapsed if the subject meets one or more of the following criteria after completion of the prior treatment regimen:

(i) an increase in proptosis of 2 mm or greater in an eye;

(ii) an absolute CAS of 4 or greater in an eye; or

(iii) a new onset of double vision; and

b) administering to the relapsed subject identified in a) said antibody, wherein said antibody administered to the relapsed subject is administered by intravenous infusion at a dosage of about 10 mg/kg as a first dose following relapse, and about 20 mg/kg in subsequent doses, and

wherein said antibody comprises a heavy chain comprising CDRH1, CDRH2, and CDRH3 and a light chain comprising CDRL1, CDRL2, and CDRL3, as set forth in SEQ ID NOs: 1-6, respectively.

20. The method of claim 19 , wherein the antibody comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 7 and a light chain variable region comprising the sequence of SEQ ID NO: 8.

21. The method of claim 20 , wherein the antibody is a human monoclonal antibody.

22. The method of claim 21 , wherein the antibody is teprotumumab.

23. The method of claim 19 , wherein the prior treatment regimen comprises intravenous infusion in a first dose of about 10 mg/kg and in subsequent doses of about 20 mg/kg.

24. The method of claim 19 , wherein the subsequent doses are administered every three weeks for at least 21 weeks.

25. The method of claim 24 , wherein the antibody is teprotumumab.

26. The method of claim 19 , wherein the relapsed subject meets the one or more of the criteria within 48 weeks after completion of the prior treatment regimen.

27. The method of claim 26 , wherein said antibody is teprotumumab, and wherein the prior treatment regimen with teprotumumab comprises administration of teprotumumab by intravenous infusion in a first dose of about 10 mg/kg and in subsequent doses of about 20 mg/kg every three weeks, for a total of eight infusions.

28. The method of claim 27 , wherein responding to the prior treatment regimen with teprotumumab comprises a reduction of 2 mm or more in proptosis in an eye.

29. The method of claim 28 , wherein administration of teprotumumab to the relapsed subject reduces proptosis by at least 2 mm in an eye and/or reduces the CAS in the subject by at least 2 points.

30. The method of claim 29 , wherein administration of teprotumumab to the relapsed subject reduces proptosis by at least 2 mm in an eye.

31. The method of claim 29 , wherein administration of teprotumumab to the relapsed subject reduces the CAS in the subject by at least 2 points.

32. The method of claim 19 , wherein said antibody is teprotumumab, and wherein administration of teprotumumab to the relapsed subject reduces proptosis by at least 2 mm in an eye and/or reduces the CAS in the subject by at least 2 points.

33. The method of claim 32 , wherein administration of teprotumumab to the relapsed subject reduces proptosis by at least 2 mm in an eye.

34. The method of claim 32 , wherein administration of teprotumumab to the relapsed subject reduces the CAS in the subject by at least 2 points.

35. The method of claim 19 , wherein the responding to the prior treatment regimen comprises a reduction of 2 mm or more in proptosis in an eye, and wherein administration of said antibody to the relapsed subject reduces proptosis by at least 2 mm in an eye.

36. A method of treating TED in a subject who has relapsed after a prior treatment regimen with teprotumumab, the method comprising:

administering teprotumumab to a subject who has relapsed after a prior treatment regimen with teprotumumab, by intravenous infusion at a dosage of about 10 mg/kg as a first dose following relapse, and in subsequent doses of about 20 mg/kg, every three weeks,

wherein the prior treatment regimen comprises administration of teprotumumab by intravenous infusion at a first dose of about 10 mg/kg and in subsequent doses of about 20 mg/kg every three weeks,

wherein the relapsed subject has relapsed after responding to the prior treatment regimen with teprotumumab,

wherein the responding to the prior treatment regimen comprises a reduction of 2 mm or more in proptosis in an eye, and

wherein the administration of teprotumumab to the relapsed subject reduces proptosis by at least 2 mm in an eye and/or reduces the CAS in said subject by at least 2 points.

37. The method of claim 36 , wherein administration of teprotumumab to the relapsed subject reduces proptosis by at least 2 mm in an eye.

38. The method of claim 36 , wherein administration of teprotumumab to the relapsed subject reduces the CAS in the subject by at least 2 points.

39. The method of claim 36 , wherein the relapsed subject meets one or more of the following criteria within 48 weeks after completion of the prior treatment regimen with teprotumumab:

(i) an increase in proptosis of 2 mm or greater in an eye;

(ii) an absolute CAS of 4 or greater in an eye; or

(iii) a new onset of double vision.

Assignments (4)
CHANGE OF ADDRESS OF ASSIGNEE Recorded Oct 22, 2025
From: HORIZON THERAPEUTICS IRELAND DAC
To: HORIZON THERAPEUTICS IRELAND DAC
Reel/Frame 073156/0404 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2023
From: HORIZON PHARMA USA, INC.
To: HORIZON THERAPEUTICS IRELAND DAC
Reel/Frame 065560/0802 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2023
From: MADDEN, DAVID; GABRIEL, KATHLEEN; MAGNI, GUIDO; WOODWARD, RICHARD; SHERMAN, JEFFREY W.
To: HORIZON THERAPEUTICS IRELAND DAC
Reel/Frame 064595/0146 →
EMPLOYMENT AGREEMENT Recorded Aug 11, 2023
From: LIN, SHAO-LEE
To: HORIZON PHARMA USA, INC.
Reel/Frame 064571/0719 →
Continuity (3)
Continuation 16293293 · Mar 5, 2019
Provisional Application 62638689 · Mar 5, 2018
Related Publication 20220340667A1 · Oct 27, 2022
References Cited (121)
US 7572897B2 · Graus et al. · 2009 [cited by applicant]
US 7579157B2 · Graus et al. · 2009 [cited by applicant]
US 8153121B2 · Smith et al. · 2012 [cited by applicant]
US 11208489B2 · Madden et al. · 2021 [cited by applicant]
US 11208490B2 · Madden et al. · 2021 [cited by applicant]
US 12209130B2 · Madden et al. · 2025 [cited by applicant]
US 20070218514A1 · Smith et al. · 2007 [cited by applicant]
US 20160287611A1 · Dobak · 2016 [cited by applicant]
US 20190225696A1 · Madden et al. · 2019 [cited by applicant]
US 20190270820A1 · Madden et al. · 2019 [cited by applicant]
US 20210284741A1 · Madden et al. · 2021 [cited by applicant]
US 20220324985A1 · Madden et al. · 2022 [cited by applicant]
US 20220356257A1 · Sherman et al. · 2022 [cited by applicant]
US 20240301072A1 · Madden et al. · 2024 [cited by applicant]
WO WO2016064716A1 · 2016 [cited by applicant]
WO WO2019173352A1 · 2019 [cited by applicant]
Bahn, RS, “Current Insights into the Pathogenesis of Graves' Ophthalmopathy”, Horm Metab Res. 47(10):773-8 (2015). [cited by applicant]
Bahn, RS, “Graves' ophthalmopathy”, N Engl J Med. 362:726-38 (2010). [cited by applicant]
Bartelena, L, et al. “Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy”, J Clin Endocrinol Metab. 97(12):4454-63 (2012). [cited by applicant]
Chen, H, et al., “Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes”, J Clin Endocrinol Metab. 99:E1635-40 (2014). [cited by applicant]
Chen, H, et al., Sichuan Da Xue Xue Bao Yi Xue Ban. 48(5):727-731 (2017). [cited by applicant]
Clinical Trials No. NCT01868997. Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease, Version 1. Reported date submitted: May 30, 2013. Date publicly available: Unknown. Date accessed: May 24, 20… [cited by applicant]
Clinical Trials No. NCT01868997. Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease, Version 2. Reported date submitted: Jun. 9, 2013. Date publicly available: Unknown. Date accessed: May 24, 20… [cited by applicant]
Clinical Trials No. NCT01868997. Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease, Version 3. Reported date submitted: Jun. 13, 2013. Date publicly available: Unknown. Date accessed: May 24, 2… [cited by applicant]
Clinical Trials No. NCT01868997. Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease, Version 4. Reported date submitted: Jun. 21, 2013 Date publicly available: Unknown. Date accessed: May 24, 20… [cited by applicant]
Clinical Trials No. NCT01868997. Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease, Version 5. Reported date submitted: Jun. 27, 2013. Date publicly available: Unknown. Date accessed: May 24, 2… [cited by applicant]
Clinical Trials No. NCT01868997. Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease, Version 6. Reported date submitted: Aug. 9, 2013. Date publicly available: Unknown. Date accessed: May 24, 20… [cited by applicant]
Clinical Trials No. NCT01868997. Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease, Version 7. Reported date submitted: Sep. 12, 2013. Date publicly available: Unknown. Date accessed: May 24, 2… [cited by applicant]
Clinical Trials No. NCT01868997. Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease, Version 8. Reported date submitted: Jan. 20, 2014. Date publicly available: Unknown. Date accessed: May 24, 2… [cited by applicant]
Clinical Trials No. NCT01868997. Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease, Version 9. Reported date submitted: Mar. 17, 2014. Date publicly available: Unknown. Date accessed: May 24, 2… [cited by applicant]
Clinical Trials No. NCT01868997. Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease, Version 10. Reported date submitted: Apr. 16, 2014. Date publicly available: Unknown. Date accessed: May 24, … [cited by applicant]
Clinical Trials No. NCT01868997. Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease, Version 11. Reported date submitted: Jul. 29, 2014. Date publicly available: Unknown. Date accessed: May 24, … [cited by applicant]
Clinical Trials No. NCT01868997. Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease, Version 12. Reported date submitted: Nov. 3, 2014. Date publicly available: Unknown. Date accessed: May 24, 2… [cited by applicant]
Clinical Trials No. NCT01868997. Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease, Version 13. Reported date submitted: Nov. 13, 2014. Date publicly available: Unknown. Date accessed: May 24, … [cited by applicant]
Clinical Trials No. NCT01868997. Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease, Version 14. Reported date submitted: Feb. 5, 2015. Date publicly available: Unknown. Date accessed: May 24, 2… [cited by applicant]
Clinical Trials No. NCT01868997. Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease, Version 15. Reported date submitted: Mar. 6, 2015. Date publicly available: Unknown. Date accessed: May 24, 2… [cited by applicant]
Clinical Trials No. NCT01868997. Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease, Version 16. Reported date submitted: Sep. 18, 2015. Date publicly available: Unknown. Date accessed: May 24, … [cited by applicant]
Clinical Trials No. NCT01868997. Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease, Version 17. Reported date submitted: Oct. 3, 2016. Date publicly available: Unknown. Date accessed: May 24, 2… [cited by applicant]
Clinical Trials No. NCT01868997. Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease, Version 18. Reported date submitted: Nov. 15, 2016. Date publicly available: Unknown. Date accessed: May 24, … [cited by applicant]
Clinical Trials No. NCT01868997. Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease, Version 19. Reported date submitted: Nov. 23, 2016. Date publicly available: Unknown. Date accessed: May 24, … [cited by applicant]
Clinical Trials No. NCT01868997. Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease, Version 20. Reported date submitted: Mar. 20, 2017. Date publicly available: Unknown. Date accessed: May 24, … [cited by applicant]
Clinical Trials No. NCT01868997. Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease, Version 21. Reported date submitted: Aug. 10, 2017. Date publicly available: Unknown. Date accessed: May 24, … [cited by applicant]
Clinical Trials No. NCT01868997. Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease, Version 22. Reported date submitted: Mar. 27, 2018. Date publicly available: Unknown. Date accessed: May 24, … [cited by applicant]
Douglas, R., et al., “Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis”, J Immunol. 178(5):3281-7 … [cited by applicant]
Douglas, R., et al., “B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis”, J Immunol. 181(8):5768-74 (2008). [cited by applicant]
Douglas, R., et al., “Increased generation of fibrocytes in thyroid-associated ophthalmopathy”, J Clin Endocrinol Metab. 95(1):430-8 (2010). [cited by applicant]
Ezra, DG, et al., ARVO Annual Meeting Scientific Abstracts (2011). [cited by applicant]
Gianoukakis, AG, et al., “Immunoglobulin G from patients with Graves' disease induces interleukin-16 and RANTES expression in cultured human thyrocytes: a putative mechanism for T-cell infiltration of the thyroid in aut… [cited by applicant]
Görtz, GE, et al., “Pathogenic Phenotype of Adipogenesis and Hyaluronan in Orbital Fibroblasts From Female Graves' Orbitopathy Mouse Model”, Endocrinology 157(10):3771-3778 (2016). [cited by applicant]
Hoa, N, et al., “Nuclear Targeting of IGF-1 Receptor in Orbital Fibroblasts from Graves' Disease: Apparent Role of ADAM17”, PLoS One. 7(4):e34173 (2012). [cited by applicant]
Hwang, CJ, et al., “Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1”, Invest Ophthalmol Vis Sci. 50(5):2262-8 (2009). [cited by applicant]
Khong, JJ, et al., “Pathogenesis of thyroid eye disease: review and update on molecular mechanisms”, Br J Ophthalmol. 100(1):142-50 (2016). [cited by applicant]
Khoo, TK, et al., “Pathogenesis of Graves' Ophthalmopathy: The Role of Autoantibodies”, Thyroid 17(10):1013-1018 (2007). [cited by applicant]
Krieger, CC, et al., “Thyroid Stimulating Hormone (TSH)/Insulin-like Growth Factor 1 (IGF1) Receptor Cross-talk in Human Cells”, Curr Opin Endocr Metab Res, 2:29-33 (2018). [cited by applicant]
Krieger, CC, et al., “TSH/IGF-1 Receptor Cross-Talk Rapidly Activates Extracellular Signal-Regulated Kinases in Multiple Cell Types”, Endocrinology 158(10):3676-3683 (2017). [cited by applicant]
Krieger, CC, et al., “TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis”, Thyroid 27(5):746-747 (2017). [cited by applicant]
Kumar, S, et al., J Clin Endocrinol Metab. 97(5):1681-7 (2012). [cited by applicant]
Kumar, S, et al., Thyroid 25(10):1145-50 (2015). [cited by applicant]
Lovell, D. J. et al., “Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis”, N Engl J Med Aug. 2008, vol. 359, pp. 810-820. [cited by applicant]
Ma, H. et al., “The Adverse Events Profile of Anti-IGF-IR Monoclonal Antibodies in Cancer Therapy”, Br J Clin Pharmacol., 77(6):917-28, (2013). [cited by applicant]
Marcus-Samuels, B, et al., Thyroid 28(5):650-655 (2018). [cited by applicant]
Naik, VM, et al., “Immunopathogenesis of thyroid eye disease: emerging paradigms”, Surv Ophthalmol. 55(3):215-26 (2010). [cited by applicant]
Pawlowski, P, et al., “Decreased Frequencies of Peripheral Blood CD4+CD25+CD127-Foxp3+ in Patients with Graves' Disease and Graves' Orbitopathy: Enhancing Effect of Insulin Growth Factor-1 on Treg Cells”, Horm Metab Res… [cited by applicant]
Place, RF, et al., “Inhibiting thyrotropin/insulin-like growth factor 1 receptor crosstalk to treat Graves' ophthalmopathy: studies in orbital fibroblasts in vitro”, Br J Pharmacol. 174(4):328-340 (2017). [cited by applicant]
Pritchard, J, et al., “Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts”, J Immunol. 168(2):942-50 (2002). [cited by applicant]
Pritchard, J, et al., “Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway”, J Immunol. … [cited by applicant]
Salvi, M., “Immunotherapy for Graves' ophthalmopathy”, Curr Opin Endocrinol Diabetes Obes. 21(5):409-14 (2014). [cited by applicant]
Salvi, M., et al., “Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study”, J Clin Endocrinol Metab. 100(2):422-31 (2015). [cited by applicant]
Smith, T, et al., “Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy”, Front Endocrinol (Lausanne) 7:167 (2017). [cited by applicant]
Smith, T, et al., “Insulin-Like Growth Factor-I Regulation of Immune Function: A Potential Therapeutic Target in Autoimmune Diseases?”, Pharmacological Rev. 62(2):199-236 (2010). [cited by applicant]
Smith, T, et al., “Pathogenesis of Graves' orbitopathy: A 2010 update”, J Endocrinol Invest. 33(6):414-21 (2010). [cited by applicant]
Smith, T, et al., “Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy”, Thyroid. 18(9):983-8 (2008). [cited by applicant]
Smith, T, et al., Best Pract Res Clin Endocrinol Metab. 26(3):291-302 (2012). [cited by applicant]
Smith, T, et al., Nat Rev Endocrinol. 11(3):171-181 (2015). [cited by applicant]
Song, D, et al., “Locally produced insulin-like growth factor-1 by orbital fibroblasts as implicative pathogenic factor rather than systemically circulated IGF-1 for patients with thyroid-associated ophthalmopathy”, Gra… [cited by applicant]
Stan, MN, et al., “Randomized controlled trial of rituximab in patients with Graves' orbitopathy”, J Clin Endocrinol Metab. 100(2):432-41 (2015). [cited by applicant]
Terwee, C. B. et al., “Development of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL”, Br J Ophthalmopathy, 1998, vol. 82, pp. 773-779. [cited by applicant]
Tsui, S, et al., “Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease”, J Immunol. 181(6):4397-405 (2008). [cited by applicant]
Ugradar, S, et al., “Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression”, Eye (Lond) 35(9):2607-2612 (2021). [cited by applicant]
Ugradar, S, et al., “Teprotumumab for the treatment of chronic thyroid eye disease”, Eye (Lond) 36(8):1553-1559 (2022). [cited by applicant]
Varewijck, AJ, et al., “Circulating IgGs may modulate IGF-I receptor stimulating activity in a subset of patients with Graves' ophthalmopathy”, J Clin Endocrinol Metab. 98(2):769-76 (2013). [cited by applicant]
Weightman, DR, et al., “Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy”, Autoimmunity 16(4):251-7 (1993). [cited by applicant]
Wiersinga, W. M. et al., “Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers”, European Journal of En… [cited by applicant]
Wiersinga, WM, Nat Clin Pract Endocrinol Metab. 3(5):396-404 (2007). [cited by applicant]
Zhang, L, et al., “Possible Targets for Nonimmunosuppressive Therapy of Graves' Orbitopathy”, J Clin Endocrinol Metab. 99(7):E1183-90 (2014). [cited by applicant]
Zhao, P, et al., “Insulin-like growth factor 1 promotes the proliferation and adipogenesis of orbital adipose-derived stromal cells in thyroid-associated ophthalmopathy”, Exp Eye Res. 107:65-73 (2013). [cited by applicant]
U.S. Appl. No. 16/256,221; Restriction Response, dated Oct. 16, 2020; 7 pages. [cited by applicant]
U.S. Appl. No. 16/256,221; Notice of Allowance, dated Aug. 23, 2021; 12 pages. [cited by applicant]
U.S. Appl. No. 16/293,293; Restriction Requirement, dated Dec. 10, 2020; 5 pages. [cited by applicant]
U.S. Appl. No. 16/293,293; Notice of Allowance, dated Aug. 20, 2021; 12 pages. [cited by applicant]
U.S. Appl. No. 17/117,625, Office Action, dated Sep. 14, 2022; 14 pages. [cited by applicant]
U.S. Appl. No. 17/531,365; Non-Final Office Action, dated Mar. 19, 2024; 18 pages. [cited by applicant]
Bagtell et al., Pharmacokinetically Guided Phase 1 Trial of the IGF-1 Receptor Antagonist RG1507 in Children with Recurrent or Refractory Solid Tumors. Clin Cancer Res., 17(3):611-9 (2011). [cited by applicant]
Bartalena et al., Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158(No. 3):273-285 (2008). [cited by applicant]
Dolman et al., Visa Classification for Graves orbitopathy. Ophthalmic Plast Reconstr Surg 22(No. 5):319-324 (2006). [cited by applicant]
Dolman., Evaluating Graves' orbitopathy. Best Pract Res Clin Endocrinol Metab 26(No. 3):229-248 (2012). [cited by applicant]
Douglas., Teprotumumab, an Insulin-Like Growth Factor-1 Receptor Antagonist Antibody, in the Treatment of Active Thyroid Eye Disease: A Focus on Proptosis. Eye (Lond) 33(2):183-90 (2019). [cited by applicant]
Gupta., Intention-to-treat concept: A review. Perspect Clin Res. 2(3):109-112 (2011). [cited by applicant]
Hansson. Aspects of growth factors in exophthalmos. Acta Endocrinologica (Copenh) 121(Suppl. 2):107-11 (1989). [cited by applicant]
Imai et al., Effect of growth factors on hyaluronan and proteoglycan synthesis by retroocular tissue fibroblasts of Graves' ophthalmopathy in culture. Acta Endocrinol (Copenh). 126(6):541-52 (1992). [cited by applicant]
Kabat et al. Sequences of Proteins of Immunological Interest. NIH Pub. No. 91-3242. Public Health Service, National Institutes of Health. 1:647-669 (1991). [cited by applicant]
Kurzrock et al., A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors. Clin Cancer Res., 16(8):2458-65 (2010). [cited by applicant]
Mourits et al., Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 47(No. 1):9-14 (1997). [cited by applicant]
Mourits et al., Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol 73(No. 8):639-644 (1989). [cited by applicant]
Pappo et al., R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Throu… [cited by applicant]
PCT/US2019/020770 International Preliminary Report on Patentability dated Sep. 17, 2020. [cited by applicant]
PCT/US2019/020770 International Search Report and Written Opinion dated Jul. 9, 2019. [cited by applicant]
Piantanida et al., Teprotumumab: A New Avenue for the Management of Moderate-to-Severe and Active Graves' Orbitopathy? J Endocrinol Invest., 40(8):885-7 (2017). [cited by applicant]
Ramalingam et al., Randomized Phase II Study of Erlotinib in Combination with Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non-Small-Cell Lung Cancer. J Clin Oncol… [cited by applicant]
Smith et al., Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab. 89(10):… [cited by applicant]
Smith et al., New Advances in Understanding Thyroid-Associated Ophthalmopathy and the Potential Role for nsulin-Like Growth Factor-I Receptor [version 1; referees: 2 approved], F1000 Research 2018, 7(F1000 Faculty Rev):… [cited by applicant]
Smith et al., Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med., 376(18):1748-61 (2017). [cited by applicant]
U.S. Appl. No. 16/256,221 Office Action dated Apr. 29, 2021. [cited by applicant]
U.S. Appl. No. 16/293,293 Office Action dated Apr. 29, 2021. [cited by applicant]
Werner., Classification of the eye changes of Graves' disease. Am J Ophthalmol 68(No. 4):646-648 (1969). [cited by applicant]
Werner., Modification of the classification of the eye changes of Graves' disease. Am J Ophthalmol 83(No. 5):725-727 (1977). [cited by applicant]
Xu et al., Comparative Efficacy of Medical Treatments for Thyroid Eye Disease: A Network Meta-Analysis. J Ophthalmol., 2018:7184163 (2018). [cited by applicant]
U.S. Appl. No. 17/531,365; Final Office Action, dated Jul. 11, 2024; 15 pages. [cited by applicant]
Xu, N. et al., “Ocular Surface Characteristics and Impression Cytology in Patients with Active versus Inactive Thyroid Eye Disease”, Eye Science, vol. 27, No. 2, pp. 64-68 (2012). [cited by applicant]
U.S. Appl. No. 17/531,365, Notice of Allowance, dated Sep. 13, 2024; 6 pages. [cited by applicant]
U.S. Appl. No. 18/929,510, Non-Final Office Action, dated Jan. 7, 2025; 15 pages. [cited by applicant]